🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. Full INAVO120 trial results: nej.md/3Zje7Vt #ASCO25 | ASCO

Presented at #ASCO25: In HER2-positive metastatic gastric cancer, trastuzumab deruxtecan led to longer survival and better response than ramucirumab–paclitaxel. Adverse events were common. Lung toxic effects with T-DXd were mainly low grade. Full DESTINY-Gastric04 trial:

Very important Insight at #ASCO25 >10% of ER -/low breast cancer patients had increased ER expression in residual tumors post-NAC ✅Retesting can unlock adjuvant endocrine therapy. ⬇️Don’t skip it if there’s residual disease! meetings.asco.org/abstracts-pres… #Oncology OncoAlert ASCO

‼️Many treatment options for locally advanced nasopharyngeal cancer (NPC) from SYSU. 💡Sparing cisplatin is an attractive strategy. ❓Which should we select for NPC patients? #ASCO25

💡MRG003, EGFR targeted ADC, Another new salvage line treatment option for recurrent or metastatic NPC. 😰How should we develop new treatment options for NPC outside China? #ASCO25

💡Darolutamide + goserelin is active for AR+ve salivary gland cancer. 🎊ORR 45%, met primary endpoint ▶️Further support to use CAB for AR+ve SGC! #ASCO25 ASCO

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer NEJM doi.org/10.1056/NEJMoa… 👉Trastuzumab deruxtecan significantly improved overall survival than ramucirumab paclitaxel 🧐Looking forward to the 1st line trials ESMO - Eur. Oncology

📈 New 1st-line standard for PIK3CA-mutant HR+/HER2– breast cancer? #ASCO25 #INAVO120 shows that inavolisib + palbociclib + fulvestrant ⌛ Chemo delayed ~2 yrs 📄 Simultaneously in NEJM: 🔗 nejm.org/doi/full/10.10… 👇 OncoAlert ASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Cristiane D Bergerot Nazli Dizman

🧬🔬🧫 First RCT success of CAR T-cell therapy in solid tumors! 📌 In CLDN18.2+ gastric cancer, Satri-cel shows: 🟣 PFS: 3.25 vs 1.77 mo 🟣 ORR: 22% vs 4% 🟣 DCR: 63% vs 25% 🔥 CRS in 95%, mostly Grade 1–2 🧠 No ICANS reported 📍 #ASCO25 | #CAR_T | #GastricCancer 📄 Lancet

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | New England Journal of Medicine ⁦OncoAlert⁩ #ASCO25 nejm.org/doi/full/10.10…

Today is National Cancer Survivors Day. These photos are some of our Ambassadors, and they represent just a fraction of the individuals who are surviving head and neck cancer. Read about their experiences:  headandneck.org/ambassador-dir…

🚨 #ASCO25 plenary NIVOPOSTOP: 1st DFS win in 20+ yrs for resected high-risk LA-SCCHN ➡️ n=666, NIVO + CRT vs CRT alone 🎉 3-yr DFS: 63.1% vs 52.5% 💥HR 0.76 (p=0.034) ⚠️ mild Gr4 AEs ⬆️ w/ NIVO (13.1% vs 5.6%) ✅ New adjuvant IO standard emerging? #hnscc #Immunotherapy #RadOnc

🎊adjuvant CRT with nivolumab demonstrated significant DFS improvement! ▶️MDT discussion is essential to selecting who should receive KN689 strategy. 💡 NivoPostOP strategy can work with weekly cisplatin. #ASCO25

What treatment options are available for one of the most aggressive forms of #ThyroidCancer? Naomi Kiyota, Taiji Koyama, and Iwao Sugitani review the latest advances in anaplastic thyroid cancer therapies. 🔗 Read the full article here: doi.org/10.1530/ETJ-24…

😰It’s really difficult to test whether we can stop IO or should continue IO after response. Unfortunately, DANTE terminated prematurely and couldn’t any conclusions. Rather we should continue IO at present. ‼️Should wait for subsequent trials to test this important CQ!#ASCO25

After Keynote689, some questions/brain storming: 💢Benefit even for PDL1 CPS/TPS negative pts? Only 16 pts per arm 🩹OS and local relapse/PD% in future IAs 💡Level of impact from neoadj part? 🩻 Benefit stratification depending mPR/neoORR? 🖋️Description of ~12% cases not

【Best of ASCO 2025 in Japan（7/5（土）・6（日））】見どころ紹介です👀✨ 乳がん：BOAJ2025乳がんではMetastaticで2セッション行います。ASCENT-04試験、DESTINY

Best of ASCO in Japanにご参加を！今年はメタバースも利用できます。是非参加して演者や司会者と直接話してみませんか？ ASCO 日本臨床腫瘍学会（JSMO） vimeo.com/1092972813/dfa… 申し込みはこちらから medicalprime.jp/event/boaj2025/

【Kernel】学術成果を公開しました。 Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial (著: Imamura Yoshinori et al.) hdl.handle.net/20.500.14094/0…

Best of ASCO in Japan 2025は昨日から開催中です。 講演の最中は抜け出しにくいですが、休み時間や開始前後などBOAラウンジに遊びに来てください。関係者がウロウロしているので、気軽に話ができますよ。#BOAJ25 vimeo.com/1092972813/dfa…